We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+12.54%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$16.6M
AUM Growth
+$2.94M
Cap. Flow
+$38.5M
Cap. Flow %
231.7%
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
4
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$37.9M
2
OM icon
Outset Medical
OM
+$6.62M
3
ESTA icon
Establishment Labs
ESTA
+$1.57M
4
CAI
Caris Life Sciences
CAI
+$1.21M
5
MGX icon
Metagenomi Therapeutics
MGX
+$1.08M

Top Sells

Rank Stock Value
1
BBNX
Beta Bionics
BBNX
+$6.04M
2
IMDX
Insight Molecular Diagnostics
IMDX
+$2.81M
3
KMTS
Kestra Medical Technologies
KMTS
+$997K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBNX
1
Beta Bionics
BBNX
$623M
$6.25M 37.57%
2,500
-426,620
-99% -$6.04M
IMDX
2
Insight Molecular Diagnostics
IMDX
$159M
$2.86M 17.2%
18,700
-928,434
-98% -$2.81M
CAI
3
Caris Life Sciences
CAI
$5.51B
$2.4M 14.45%
+45,000
New +$1.21M
ESTA icon
4
Establishment Labs
ESTA
$2.57B
$1.92M 11.56%
89,940
+44,940
+100% +$1.57M
OM icon
5
Outset Medical
OM
$96.9M
$1.36M 8.18%
429,120
+424,120
+8,482% +$6.62M
NSPR icon
6
InspireMD
NSPR
$34.2M
$1.02M 6.15%
450,517
– –
NTRA icon
7
Natera
NTRA
$38.2B
$422K 2.54%
245,691
+243,191
+9,728% +$37.9M
MGX icon
8
Metagenomi Therapeutics
MGX
$45.9M
$391K 2.35%
952,134
+687,743
+260% +$1.08M
KMTS
9
Kestra Medical Technologies
KMTS
$1.45B
– –
-40,000
Closed -$997K

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
ONGA
O'Neil Global Advisors Los Angeles, California $14.4M AUM 220.73% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
PA
PPM America Chicago, Illinois $16.6M AUM 31.99% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Pura Vida Investments's Q2 2025 Portfolio in Review

As of Q2 2025, Pura Vida Investments held 9 positions worth $16.6M, up 21% from $13.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Pura Vida Investments deployed $38.5M of net new capital in Q2 2025, opening 1 new position and adding to 4 existing holdings. Its largest new stake was Caris Life Sciences: 45,000 shares worth $2.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Beta Bionics, an estimated $6.04M trimmed.

  • Pura Vida Investments's largest Q2 2025 buy was Caris Life Sciences: 45,000 shares worth $2.4M.
  • Pura Vida Investments added most to Natera in Q2 2025, an estimated $37.9M increase.
  • Pura Vida Investments's biggest Q2 2025 reduction was Beta Bionics, cutting an estimated $6.04M.
  • Pura Vida Investments fully exited Kestra Medical Technologies in Q2 2025, selling an estimated $997K.
  • Pura Vida Investments's ten largest holdings make up 100% of its $16.6M portfolio in Q2 2025.
  • Pura Vida Investments opened 1 new position and closed 1 in Q2 2025.
  • Pura Vida Investments's portfolio value rose 21% quarter-over-quarter to $16.6M.

Based on Pura Vida Investments's 13F filing for Q2 2025, filed 13 Aug 2025.